Randomized trial · people
Petrelintide: up to 8.6% weight loss at 16 weeks in phase 1
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Early human data show weekly petrelintide brought weight loss of up to 8.6% over 16 weeks with mostly mild nausea and no serious side effects, but this is dose-testing work, not a large or long trial.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2026
- Journal
- Diabetes Obes Metab
What they tested
The team tested how safe and well tolerated petrelintide, a long-acting amylin analogue, was, how the body handled it, and what it did to body weight.
How the study was done
Two randomized, double-blind, placebo-controlled phase 1 trials (early-stage human testing, with a dummy shot for comparison): one gave single doses under the skin from 0.04 to 2.4 mg, plus one 0.35 mg dose into a vein, and the other gave repeated weekly shots under the skin. In the repeated-dose trial, part 1 gave 6 weekly doses of 0.6 or 1.2 mg to adults of normal weight or overweight, and part 2 gave 16 weekly doses, stepped up every 2 weeks to target doses of 2.4, 4.8 or 9.0 mg, to adults with overweight or obesity.

Model. Individual results vary.
What they found
No one had a serious or severe side effect, and the most common ones were stomach and gut problems, mostly mild. In part 2 of the repeated-dose trial, nausea occurred in 16.7%-33.3% of people on petrelintide versus 16.7% on placebo; diarrhea was rare, and only one person vomited, the same person who stopped treatment because of gut side effects. The drug was absorbed slowly, had a half-life (the time for half of it to leave the body) of about 10 days, and body weight fell by up to 8.6% after 16 weeks.
What it doesn’t show
These were early phase 1 trials built mainly to test safety and dosing, and the longest dosing lasted only 16 weeks. They don't show how petrelintide performs over longer periods or in larger groups of people with obesity.
The paper
Brændholt Olsen et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes Obes Metab. 2026.
The compound
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.